Figure 4. . Summary of eligibility criteria broadening decision across the 9 historical Relapsed and refractory multiple myeloma trials using Optum's electronic health records and Flatiron Health.

Decision making was based on the number of patients change and Shapley values. Real-world databases Optum's EHR and Flatiron Health are referred as O and F respectively. *Indicates trial with presence of trend efficacy result between RCT and RWE studies.

APO.: APOLLA; ASP.: ASPIRE; CAN.: CANDOR; CAS: CASTOR; COPD: Chronic obstructive pulmonary disease; ECOG: Eastern Cooperative Oncology Group; EHR: Electronic health record; ELO2: ELOQUENT; END.: ENDEAVOR; IGM: Immunoglobulin; MS: Myelodysplastic syndrome; NIM.: NIMBUS; PI: Proteasome inhibitor; POEMS: Polyneuropathy, organomegaly, endocrinopathy/edema, monoclonal-protein and skin changes; POL.: POLLUX; TOUR.: TOURMALINE; WM: Waldenström’s macroglobulinemia.